STAT2 R148 variant: A 16th-century founder mutation and clinical response to high-dose JAK inhibitor therapy. - Parvaneh N; Molatefi R; Gruber C; Biglari S; Moradi L; Seeleuthner Y; Ailal F; Bousfiha AA; Pak N; Soudée C; Casanova JL; Rosain J; et al. (Journal of human immunity, 2026)